{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:26:38Z","timestamp":1788323198574,"version":"build-2803163510"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008738","name":"Jeanssons Stiftelser","doi-asserted-by":"publisher","award":["JS2018-0084"],"award-info":[{"award-number":["JS2018-0084"]}],"id":[{"id":"10.13039\/100008738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004472","name":"Riksbankens Jubileumsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004472","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21875"],"award-info":[{"award-number":["21875"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["22248"],"award-info":[{"award-number":["22248"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Fondazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["22558"],"award-info":[{"award-number":["22558"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["SLS-89022"],"award-info":[{"award-number":["SLS-89022"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cellsig.2019.109468","type":"journal-article","created":{"date-parts":[[2019,11,9]],"date-time":"2019-11-09T11:12:56Z","timestamp":1573297976000},"page":"109468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium"],"prefix":"10.1016","volume":"66","author":[{"given":"Jean Piero","family":"Margaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Cosimo","family":"Campa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2019.109468_bb0005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.cell.2017.07.029","article-title":"The PI3K pathway in human disease","volume":"170","author":"Fruman","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0010","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research N","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0020","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","article-title":"Renal cancer","volume":"387","author":"Capitanio","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2019.109468_bb0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cellsig.2019.109468_bb0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molmed.2011.06.003","article-title":"mTOR signaling in polycystic kidney disease","volume":"17","author":"Ibraghimov-Beskrovnaya","year":"2011","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0035","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.2215\/CJN.01360210","article-title":"Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases","volume":"5","author":"Torres","year":"2010","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0040","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028209","article-title":"Ciliary mechanisms of cyst formation in polycystic kidney disease","volume":"9","author":"Ma","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0045","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10157-016-1289-1","article-title":"Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells","volume":"21","author":"de Stephanis","year":"2017","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0050","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/MCB.01259-08","article-title":"Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1","volume":"29","author":"Distefano","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0055","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41598-018-22938-x","article-title":"Dual mTOR\/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease","volume":"8","author":"Liu","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2019.109468_bb0060","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.celrep.2018.06.106","article-title":"mTORC1 upregulation leads to accumulation of the Oncometabolite fumarate in a mouse model of renal cell carcinoma","volume":"24","author":"Drusian","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2019.109468_bb0065","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0092-8674(87)90168-1","article-title":"Common elements in growth factor stimulation and oncogenic transformation: 85 kd phosphoprotein and phosphatidylinositol kinase activity","volume":"50","author":"Kaplan","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0070","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/315239a0","article-title":"Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation","volume":"315","author":"Whitman","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0080","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3109\/07853890.2014.912836","article-title":"PI3K\/AKT signaling pathway and cancer: an updated review","volume":"46","author":"Martini","year":"2014","journal-title":"Ann. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0085","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell Cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccr.2009.10.016","article-title":"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation","volume":"16","author":"Jaiswal","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0095","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.tcb.2019.01.001","article-title":"Class II PI3K functions in cell biology and disease","volume":"29","author":"Gulluni","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0100","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2017.09.002","article-title":"Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2alpha scaffolding function","volume":"32","author":"Gulluni","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0105","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1681\/ASN.2014100967","article-title":"Phosphoinositide 3-kinase-C2alpha regulates Polycystin-2 ciliary entry and protects against kidney cyst formation","volume":"27","author":"Franco","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers7010001","article-title":"Regulation of the tumor-suppressor function of the class III phosphatidylinositol 3-kinase complex by ubiquitin and SUMO","volume":"7","author":"Reidick","year":"2014","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2019.109468_bb0115","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc2842","article-title":"Phosphoinositide signalling in cancer: beyond PI3K and PTEN","volume":"10","author":"Bunney","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2019.109468_bb0120","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10555-009-9198-3","article-title":"Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer","volume":"28","author":"Knowles","year":"2009","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.cellsig.2019.109468_bb0125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/0008-5472.CAN-10-2488","article-title":"PTEN level in tumor suppression: how much is too little?","volume":"71","author":"Carracedo","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2019.109468_bb0130","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.cellsig.2013.03.025","article-title":"Cell survival and metastasis regulation by Akt signaling in colorectal cancer","volume":"25","author":"Agarwal","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2019.109468_bb0135","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0968-0004(97)01097-9","article-title":"PKB\/Akt: connecting phosphoinositide 3-kinase to cell survival and beyond","volume":"22","author":"Marte","year":"1997","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.cellsig.2019.109468_bb0145","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/nm761","article-title":"PKB\/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest","volume":"8","author":"Liang","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0150","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/nm759","article-title":"PKB\/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization","volume":"8","author":"Shin","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0155","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/nm762","article-title":"Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB\/Akt-mediated phosphorylation in breast cancer","volume":"8","author":"Viglietto","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0160","doi-asserted-by":"crossref","first-page":"5648","DOI":"10.1038\/onc.2008.170","article-title":"AKT1(E17K) in human solid tumours","volume":"27","author":"Bleeker","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.cellsig.2019.109468_bb0165","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"Carpten","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0170","doi-asserted-by":"crossref","first-page":"7002","DOI":"10.1158\/0008-5472.CAN-04-1399","article-title":"Deregulated Akt3 activity promotes development of malignant melanoma","volume":"64","author":"Stahl","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2019.109468_bb0175","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2019.109468_bb0185","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1126\/science.1228792","article-title":"Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1","volume":"339","author":"Ben-Sahra","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2019.109468_bb0190","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1126\/science.aad0489","article-title":"mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle","volume":"351","author":"Ben-Sahra","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2019.109468_bb0195","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.1228771","article-title":"Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis","volume":"339","author":"Robitaille","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2019.109468_bb0200","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2018.00126","article-title":"Signaling pathways regulating redox balance in cancer metabolism","volume":"8","author":"De Santis","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1042\/BJ20081668","article-title":"mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)","volume":"416","author":"Garcia-Martinez","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.cellsig.2019.109468_bb0210","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2019.109468_bb0215","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.devcel.2006.10.007","article-title":"Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1","volume":"11","author":"Guertin","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cell.2006.08.033","article-title":"SIN1\/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity","volume":"127","author":"Jacinto","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0225","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0230","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1471-2407-8-282","article-title":"TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells","volume":"8","author":"Hietakangas","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cellsig.2019.109468_bb0235","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0240","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cell.2005.02.031","article-title":"Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis","volume":"121","author":"Ma","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0245","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41581-018-0059-6","article-title":"Renal disease in tuberous sclerosis complex: pathogenesis and therapy","volume":"14","author":"Lam","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0250","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nature11310","article-title":"Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice","volume":"488","author":"Tsai","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0255","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/gcc.2870130411","article-title":"Loss of heterozygosity in the tuberous sclerosis (TSC2) region of chromosome band 16p13 occurs in sporadic as well as TSC-associated renal angiomyolipomas","volume":"13","author":"Henske","year":"1995","journal-title":"Genes. Chrom. Cancer"},{"key":"10.1016\/j.cellsig.2019.109468_bb0260","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/hmg\/ddu597","article-title":"A shower of second hit events as the cause of multifocal renal cell carcinoma in tuberous sclerosis complex","volume":"24","author":"Tyburczy","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0265","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1172\/JCI72272","article-title":"Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease","volume":"124","author":"Harris","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2019.109468_bb0270","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1681\/ASN.2017080878","article-title":"Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease","volume":"29","author":"Tan","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9040030","article-title":"PI3K Signaling in tissue hyper-proliferation: from overgrowth syndromes to kidney cysts","volume":"9","author":"De Santis","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2019.109468_bb0280","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/ndt\/gfn744","article-title":"Activation of the AKT\/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD)","volume":"24","author":"Fischer","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cellsig.2019.109468_bb0285","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2019.109468_bb0290","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1093\/hmg\/ddp398","article-title":"Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1","volume":"18","author":"Zhou","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0295","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/emboj.2008.96","article-title":"pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation","volume":"27","author":"Frew","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2019.109468_bb0300","doi-asserted-by":"crossref","first-page":"18722","DOI":"10.1073\/pnas.0908853106","article-title":"Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2","volume":"106","author":"Hasumi","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2019.109468_bb0305","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","article-title":"The cancer genome atlas comprehensive molecular characterization of renal cell carcinoma","volume":"23","author":"Ricketts","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.cellsig.2019.109468_bb0310","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060844","article-title":"PTEN hamartoma tumor syndrome: a clinical overview","volume":"11","author":"Pilarski","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cellsig.2019.109468_bb0315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41581-018-0051-1","article-title":"Metabolism and mitochondria in polycystic kidney disease research and therapy","volume":"14","author":"Padovano","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0320","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000314380","article-title":"The mTOR pathway is activated in human autosomal-recessive polycystic kidney disease","volume":"33","author":"Becker","year":"2010","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.cellsig.2019.109468_bb0325","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1111\/jcmm.13091","article-title":"Rapamycin treatment dose-dependently improves the cystic kidney in a new ADPKD mouse model via the mTORC1 and cell-cycle-associated CDK1\/cyclin axis","volume":"21","author":"Li","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0330","article-title":"Activation of the PI3K\/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat","volume":"9","author":"Ren","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2019.109468_bb0335","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1294-328","article-title":"Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome","volume":"8","author":"Brook-Carter","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0340","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009239","article-title":"Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR","volume":"5","author":"Dere","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.cellsig.2019.109468_bb0345","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.4161\/cc.5.21.3408","article-title":"Regulation of mTOR by polycystin-1: is polycystic kidney disease a case of futile repair?","volume":"5","author":"Weimbs","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.cellsig.2019.109468_bb0350","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1091\/mbc.e07-02-0142","article-title":"Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion","volume":"18","author":"Boca","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0355","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1681\/ASN.2005050534","article-title":"Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase\/Akt signaling pathway","volume":"17","author":"Boca","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0360","doi-asserted-by":"crossref","first-page":"9388","DOI":"10.1074\/jbc.RA118.001723","article-title":"Long noncoding RNA Hoxb3os is dysregulated in autosomal dominant polycystic kidney disease and regulates mTOR signaling","volume":"293","author":"Aboudehen","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2019.109468_bb0365","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-2-6","article-title":"Emerging evidence of a link between the polycystins and the mTOR pathways","volume":"2","author":"Boletta","year":"2009","journal-title":"Pathogenetics"},{"key":"10.1016\/j.cellsig.2019.109468_bb0370","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nature14190","article-title":"Nutrient-sensing mechanisms and pathways","volume":"517","author":"Efeyan","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0375","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrneph.2016.108","article-title":"Roles of mTOR complexes in the kidney: implications for renal disease and transplantation","volume":"12","author":"Fantus","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0380","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0385","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bph.14558","article-title":"The combination of metformin and 2-deoxyglucose significantly inhibits cyst formation in miniature pigs with polycystic kidney disease","volume":"176","author":"Lian","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/ndt\/gfq384","article-title":"Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats","volume":"26","author":"Renken","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cellsig.2019.109468_bb0395","doi-asserted-by":"crossref","first-page":"F236","DOI":"10.1152\/ajprenal.00129.2010","article-title":"mTORC1\/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease","volume":"300","author":"Belibi","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0400","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/ncb2117","article-title":"Primary cilia regulate mTORC1 activity and cell size through Lkb1","volume":"12","author":"Boehlke","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0405","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrm.2017.60","article-title":"Genes and molecular pathways underpinning ciliopathies","volume":"18","author":"Reiter","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.cellsig.2019.109468_bb0410","doi-asserted-by":"crossref","DOI":"10.1186\/s13630-017-0046-8","article-title":"CILIA: before and after","volume":"6","author":"Satir","year":"2017","journal-title":"Cilia"},{"key":"10.1016\/j.cellsig.2019.109468_bb0415","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.biocel.2010.06.017","article-title":"Polycystin-1: function as a mechanosensor","volume":"42","author":"Dalagiorgou","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0420","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ng1076","article-title":"Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells","volume":"33","author":"Nauli","year":"2003","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0425","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/s41467-018-03036-y","article-title":"Lkb1 deficiency confers glutamine dependency in polycystic kidney disease","volume":"9","author":"Flowers","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2019.109468_bb0430","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/hmg\/ddn325","article-title":"The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway","volume":"18","author":"Hartman","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0435","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/hmg\/ddp149","article-title":"Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis","volume":"18","author":"Bonnet","year":"2009","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0440","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1007\/s00018-018-2761-8","article-title":"TSC1 and TSC2 regulate cilia length and canonical hedgehog signaling via different mechanisms","volume":"75","author":"Rosengren","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.cellsig.2019.109468_bb0445","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/15548627.2015.1023983","article-title":"Reciprocal regulation of cilia and autophagy via the MTOR and proteasome pathways","volume":"11","author":"Wang","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.cellsig.2019.109468_bb0450","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/ncb3360","article-title":"Primary-cilium-dependent autophagy controls epithelial cell volume in response to fluid flow","volume":"18","author":"Orhon","year":"2016","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0455","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10786","article-title":"mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex","volume":"7","author":"Pema","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2019.109468_bb0460","doi-asserted-by":"crossref","first-page":"5482","DOI":"10.1038\/ncomms6482","article-title":"Ciliary membrane proteins traffic through the Golgi via a Rabep1\/GGA1\/Arl3-dependent mechanism","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2019.109468_bb0465","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S1097-2765(01)00226-X","article-title":"Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene","volume":"7","author":"Kleymenova","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0470","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.krcp.2012.07.002","article-title":"Mammalian target of rapamycin inhibition in polycystic kidney disease: from bench to bedside","volume":"31","author":"Kim","year":"2012","journal-title":"Kidney Res Clin Pract"},{"key":"10.1016\/j.cellsig.2019.109468_bb0475","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJMe1006925","article-title":"mTOR inhibitors in polycystic kidney disease","volume":"363","author":"Watnick","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0480","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0092-8674(94)90570-3","article-title":"RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs","volume":"78","author":"Sabatini","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0485","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.cellsig.2019.109468_bb0490","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cmet.2014.01.001","article-title":"Rapamycin: one drug, many effects","volume":"19","author":"Li","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2019.109468_bb0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/CE.S98687","article-title":"Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy","volume":"11","author":"Buti","year":"2016","journal-title":"Core Evid"},{"key":"10.1016\/j.cellsig.2019.109468_bb0500","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/13543784.2017.1384813","article-title":"Clinical development of mTor inhibitors for renal cancer","volume":"26","author":"Ghidini","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.cellsig.2019.109468_bb0505","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/ki.2009.147","article-title":"Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis","volume":"76","author":"Gattone","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.cellsig.2019.109468_bb0510","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0515","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000104818","article-title":"Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease","volume":"30","author":"Wu","year":"2007","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.cellsig.2019.109468_bb0520","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1681\/ASN.2009121302","article-title":"Sirolimus therapy to halt the progression of ADPKD","volume":"21","author":"Perico","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0525","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1681\/ASN.2007050626","article-title":"Sirolimus reduces polycystic liver volume in ADPKD patients","volume":"19","author":"Qian","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0530","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0535","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0540","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMc1010845","article-title":"mTOR inhibitors and autosomal dominant polycystic kidney disease","volume":"364","author":"Grantham","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0545","doi-asserted-by":"crossref","first-page":"pe24","DOI":"10.1126\/scisignal.267pe24","article-title":"The pharmacology of mTOR inhibition","volume":"2","author":"Guertin","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2019.109468_bb0550","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/ndt\/gfu296","article-title":"An mTOR kinase inhibitor slows disease progression in a rat model of polycystic kidney disease","volume":"30","author":"Ravichandran","year":"2015","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.cellsig.2019.109468_bb0555","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbcan.2019.03.003","article-title":"Targeting PI3K signaling in cancer: challenges and advances","volume":"1871","author":"De Santis","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.cellsig.2019.109468_bb0560","doi-asserted-by":"crossref","first-page":"785","DOI":"10.2215\/CJN.09900915","article-title":"Effect of Sirolimus on disease progression in patients with autosomal dominant polycystic kidney disease and CKD stages 3b-4","volume":"11","author":"Ruggenenti","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0565","doi-asserted-by":"crossref","first-page":"F395","DOI":"10.1152\/ajprenal.00057.2018","article-title":"Comparison of folate-conjugated rapamycin versus unconjugated rapamycin in an orthologous mouse model of polycystic kidney disease","volume":"315","author":"Kipp","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.cellsig.2019.109468_bb0570","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1681\/ASN.2012040367","article-title":"Folate-conjugated rapamycin slows progression of polycystic kidney disease","volume":"23","author":"Shillingford","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0575","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1172\/JCI73935","article-title":"mTORC2 regulates renal tubule sodium uptake by promoting ENaC activity","volume":"125","author":"Gleason","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2019.109468_bb0580","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1172\/JCI80304","article-title":"mTORC2 critically regulates renal potassium handling","volume":"126","author":"Grahammer","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2019.109468_bb0585","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1681\/ASN.2015111224","article-title":"mTOR regulates endocytosis and nutrient transport in proximal tubular cells","volume":"28","author":"Grahammer","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0590","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1172\/JCI44771","article-title":"mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice","volume":"121","author":"Inoki","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2019.109468_bb0595","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2215\/CJN.02650313","article-title":"Low-dose rapamycin (sirolimus) effects in autosomal dominant polycystic kidney disease: an open-label randomized controlled pilot study","volume":"9","author":"Braun","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0600","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13063-015-0692-3","article-title":"Pulsed oral sirolimus in advanced autosomal-dominant polycystic kidney disease (Vienna RAP study): study protocol for a randomized controlled trial","volume":"16","author":"Riegersperger","year":"2015","journal-title":"Trials"},{"key":"10.1016\/j.cellsig.2019.109468_bb0605","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/ncb1579","article-title":"pVHL and GSK3beta are components of a primary cilium-maintenance signalling network","volume":"9","author":"Thoma","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0610","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/hmg\/ddw097","article-title":"Inpp5e suppresses polycystic kidney disease via inhibition of PI3K\/Akt-dependent mTORC1 signaling","volume":"25","author":"Hakim","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0615","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymeth.2014.10.002","article-title":"Study of PTEN subcellular localization","volume":"77-78","author":"Bononi","year":"2015","journal-title":"Methods"},{"key":"10.1016\/j.cellsig.2019.109468_bb0620","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/ng.423","article-title":"Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies","volume":"41","author":"Bielas","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0625","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/ng.427","article-title":"INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse","volume":"41","author":"Jacoby","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0630","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.devcel.2015.06.016","article-title":"Modulation of ciliary phosphoinositide content regulates trafficking and sonic hedgehog signaling output","volume":"34","author":"Ch\u00e1vez","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0635","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.devcel.2015.08.001","article-title":"Phosphoinositides regulate ciliary protein trafficking to modulate hedgehog signaling","volume":"34","author":"Garcia-Gonzalo","year":"2015","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0640","doi-asserted-by":"crossref","first-page":"20110","DOI":"10.1074\/jbc.M910119199","article-title":"The isolation and characterization of a cDNA encoding phospholipid-specific inositol polyphosphate 5-phosphatase","volume":"275","author":"Kisseleva","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellsig.2019.109468_bb0645","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1101\/gad.1966210","article-title":"TULP3 bridges the IFT-A complex and membrane phosphoinositides to promote trafficking of G protein-coupled receptors into primary cilia","volume":"24","author":"Mukhopadhyay","year":"2010","journal-title":"Genes Dev."},{"key":"10.1016\/j.cellsig.2019.109468_bb0650","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1093\/hmg\/dds163","article-title":"OCRL localizes to the primary cilium: a new role for cilia in Lowe syndrome","volume":"21","author":"Luo","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0655","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1242\/jcs.200857","article-title":"Loss of OCRL increases ciliary PI(4,5)P2 in Lowe oculocerebrorenal syndrome","volume":"130","author":"Prosseda","year":"2017","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.cellsig.2019.109468_bb0660","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.devcel.2014.01.022","article-title":"PI3K class II \u03b1 controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function","volume":"28","author":"Franco","year":"2014","journal-title":"Dev. Cell"},{"key":"10.1016\/j.cellsig.2019.109468_bb0665","doi-asserted-by":"crossref","DOI":"10.3390\/biom9030104","article-title":"Class II PI3Ks at the intersection between signal transduction and membrane trafficking","volume":"9","author":"Margaria","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.cellsig.2019.109468_bb0670","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/nm.2928","article-title":"Endothelial PI3K-C2\u03b1, a class II PI3K, has an essential role in angiogenesis and vascular barrier function","volume":"18","author":"Yoshioka","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.cellsig.2019.109468_bb0675","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.febslet.2015.05.001","article-title":"PI3K-C2alpha: one enzyme for two products coupling vesicle trafficking and signal transduction","volume":"589","author":"Campa","year":"2015","journal-title":"FEBS Lett."},{"key":"10.1016\/j.cellsig.2019.109468_bb0680","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nature12360","article-title":"Spatiotemporal control of endocytosis by phosphatidylinositol-3,4-bisphosphate","volume":"499","author":"Posor","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2019.109468_bb0685","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jbior.2016.09.002","article-title":"Rab11 and phosphoinositides: a synergy of signal transducers in the control of vesicular trafficking","volume":"63","author":"Campa","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.cellsig.2019.109468_bb0690","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41589-018-0086-4","article-title":"Rab11 activity and PtdIns(3)P turnover removes recycling cargo from endosomes","volume":"14","author":"Campa","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.cellsig.2019.109468_bb0695","doi-asserted-by":"crossref","first-page":"6346","DOI":"10.1073\/pnas.1002401107","article-title":"Coordination of Rab8 and Rab11 in primary ciliogenesis","volume":"107","author":"Kn\u00f6dler","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.cellsig.2019.109468_bb0700","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0022-3476(99)70417-8","article-title":"Medical complications in long-term survivors with X-linked myotubular myopathy","volume":"134","author":"Herman","year":"1999","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cellsig.2019.109468_bb0705","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/hmg\/ddr512","article-title":"Modeling the human MTM1 p.R69C mutation in murine Mtm1 results in exon 4 skipping and a less severe myotubular myopathy phenotype","volume":"21","author":"Pierson","year":"2012","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.cellsig.2019.109468_bb0710","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1038\/s41467-018-07464-8","article-title":"The phospholipid PI(3,4)P","volume":"9","author":"Rom\u00e1n-Fern\u00e1ndez","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2019.109468_bb0715","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008088","article-title":"Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction","volume":"15","author":"Tiosano","year":"2019","journal-title":"PLoS Genet."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656819302645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656819302645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:52:23Z","timestamp":1760266343000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656819302645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":143,"alternative-id":["S0898656819302645"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2019.109468","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PI3K\/Akt\/mTOR pathway in polycystic kidney disease: A complex interaction with polycystins and primary cilium","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2019.109468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109468"}}